In a recent paper, researchers described a new metric called the Parkinson’s Disease Social Functioning Scale (PDSFS) that aims to measure social functioning in patients with this disease.
How people engage with one another, and in society at large, is known as social functioning, but how social functioning is affected in patients without dementia who have Parkinson disease (PD) has not been widely studied. In a recent paper, researchers described a new metric called the Parkinson’s Disease Social Functioning Scale (PDSFS) that aims to measure social functioning in this population.
Impairment in social functioning may be one of those prodromal symptoms of PD that begin to emerge years before motor symptoms appear. In this study, the researchers wanted to see whether PDSFS scores are linked with cognitive status with PD. The PDSFS assesses family life, self-care, hobbies, interpersonal relationships, and social bonds.
A total of 302 participants were recruited, 181 with PD and 121 healthy adults who served as controls. Of the 181 patients with PD, 55 had mild cognitive impairment (MCI) and 126 were considered cognitively intact (CI). All underwent the Mini-Mental State Examination (MMSE) and PDSFS; 120 patients with PD completed the MMSE, Activities of Daily Living Scale and Neuropsychiatric Inventory.
The analysis included group comparisons, receiver operating characteristic curves, Spearman correlation and multiple and hierarchical regression analyses.
The analysis showed that patients with PD-MCI scored the lowest in all areas of the PDSFS (F = 10.10, P < 0.001).
The PDSFS cut-off score for PD-MCI was 53 (area under the curve 0.700, sensitivity 0.800, specificity 0.534). The low specificity indicates that a score between 40 and 53 for patients with PD means that “they were likely to experience challenges with their social functioning when dealing with complex functional tasks.”
The PDSFS score was predicted by the MMSE (β = 0.293, P = .002), Activities of Daily Living Scale (β = 0.189, P = .028), and the Neuropsychiatric Inventory (β = −0.216, P = .005).
Researchers also found an interaction effect between the Activities of Daily Living Scale and Neuropsychiatric Inventory scores on the PDSFS (β = 0.305, P < .001).
However, PDSFS scores were not significantly linked with demographics or measures of Parkinson’s severity.
Participants in the PD-CI group had similar social functioning as the healthy controls, although they were lower in areas related to social bonds; the authors suggested that PD creates issues of loneliness and isolation even when cognitive problems are not present.
“Although the overall social functioning of the of the PD-CI group is not different from that of healthy older adults, the impairment of ‘social bond’ cannot be ignored,” the researchers wrote.
In addition, “neuropsychiatric symptoms may influence patients’ social functioning,” the authors said.
The study was published in BJPsych Open.
Reference
Chen YR, Tan CH, Su HC, et al. Investigating the interaction between neuropsychiatry features and daily activities on social function in patients with Parkinson's disease with mild cognitive impairment. BJPsych Open. Published online November 25, 2022. doi.org/10.1192/bjo.2022.611
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More
2 Commerce Drive
Cranbury, NJ 08512